Ravos

• Protocol  132190
• Patienteninformatie Nederlands  132189
• Patienteninformatie Engels  132188

Documenten alleen te vinden op intranet

This mono-center case-control study will be conducted in the Amsterdam UMC, location AMC. SCD patients will be selected out of the large cohort of 300 patients. Since patients with HbSS and HbSC genotypes often have different clinical manifestations regarding organ damage, both genotypes will be included in this study to compare them. For both genotypes, a control group consisting of patients with the same genotype but without SCR will be recruited (matched for age, genotype and gender) in order to test differences between these groups in red cell characteristics, angiogenesis markers, viscosity and retinal oxygenation parameters. In total, four patient groups with 20 patients per group will be selected.
We aim to collect all required venous blood samples and clinical data within one year.

In order to be eligible to participate in this study, a subject must meet all of the following criteria:
 Minimum age of 18 years
 HbSC or HbSS genotype
 Recent ophthalmologic examination (up to 2 years prior) or (willingness to attend) upcoming examination

Veiligheidsinformatie

nvt

nvt

• Vragen, bijzonderheden en SAE meldingen primair via behandelend /dienstdoend hematoloog en/of trialbureau (via het secretariaat hematologie 020-4442604) of specifiek:
  • Bij AML, CML, CLL, ALL, MDS, MF en GvHD: Trialbureauleukemie@amsterdamumc.nl
  • Bij Plasmaceldyscrasie: Trialbureaumultipelmyeloom@amsterdamumc.nl
  • Bij Non-Hodgkin lymfomen en Hodkin Lymfoom: Trialbureaulymfoid@amsterdamumc.nl
  • Bij niet oncologische hematologie: TB_benignehematologie@amsterdamumc.nl